|Home | About | Journals | Submit | Contact Us | Français|
Fibrin deposition and thrombosis within the microvasculature is now appreciated to play a pivotal role in the hepatocellular injury observed in experimental and human viral hepatitis. Importantly, the pathways by which fibrin generation is elicited in viral hepatitis may be mechanistically distinct from the classical pathways of coagulation induced by mechanical trauma or bacterial lipopolysaccharide (LPS). In the setting of murine hepatitis virus strain-3 (MHV-3) infection, a member of the Coronaviridae, activated endothelial cells and macrophages express distinct cell-surface procoagulants, including a novel prothrombinase, Fgl2/fibroleukin, which are important for both the initiation and localization of fibrin deposition. To assess the role of Fgl2/fibroleukin in murine viral hepatitis we generated a Fgl2/fibroleukin–deficient mouse. Peritoneal macrophages isolated from Fgl2/fibroleukin–/– mice did not generate a procoagulant response when infected with MHV-3. Fibrin deposition and liver necrosis were markedly reduced, and survival was increased in mice infected with MHV-3. To address the relevance of Fgl2/fibroleukin in human chronic viral hepatitis we studied patients with minimal and marked chronic hepatitis B. We detected robust expression of Fgl2/fibroleukin mRNA transcripts and protein in liver tissue isolated from patients with marked chronic hepatitis B. Fibrin deposition was strongly associated with Fgl2/fibroleukin expression. Collectively, these data indicate a critical role for Fgl2/fibroleukin in the pathophysiology of experimental and human viral hepatitis.
Many of the viral pathogens known to cause liver disease are not directly cytopathic for the hepatocyte. For instance, the acute and chronic liver diseases caused by the hepatitis B virus reflect hepatocellular injury induced by an immune response to the virus rather than direct viral-induced hepatocellular necrosis. For example, IFN-γ derived from activated T cells within the liver figures prominently in viral-induced liver disease in humans as well as in animal models (1). Another especially important effector phase in the immune response to viral infection of the liver is fibrin deposition and thrombosis within the microvasculature (2). This is an important concept that offers hope for the development of novel treatment approaches to viral-induced liver disease. Herein we provide new insight into the importance of novel immune procoagulants in the pathogenesis of viral hepatitis.
Tissue factor (TF), the transmembrane receptor for factor VII, is the major procoagulant for the classical pathway and is known to initiate the extrinsic pathway of coagulation in response to LPS (3, 4). In the presence of calcium, the TF/factor VIIa complex activates the zymogen precursor factor X. Factor Xa is a serine protease that is the classically known physiological activator of prothrombin. Efficient thrombin generation by factor Xa requires calcium, an electronegative phospholipid surface, and the nonenzymatic cofactor, factor Va. Current evidence indicates that the pathways by which vascular thromboses are elicited in viral hepatitis are mechanistically distinct from the classical pathways of coagulation induced by mechanical trauma or bacterial lipopolysaccharide (LPS). The in vitro induction of a procoagulant response in mononuclear cells by murine hepatitis virus type-3 (MHV-3) correlates with the disease susceptibility in strains of mice (5). MHV-3 is a member of the Coronaviridae, a group of positive-stranded, enveloped RNA viruses. Peritoneal macrophages from BALB/c or C57Bl/6 mice, strains in which MHV-3 infection results in fatal acute fulminant hepatitis, respond to the virus with a robust procoagulant response. In contrast, peritoneal macrophages from A/J mice, a strain fully resistant to MHV-3, generate no increase in procoagulant above control levels. This procoagulant response represented a functional marker for susceptibility to MHV-3 infection in inbred strains of mice, suggesting that this response is important in the pathogenesis of coronavirus MHV-3–induced disease.
Activated endothelial cells and macrophages express distinct cell-surface procoagulants important for both the initiation and localization of fibrin deposition in viral-induced liver disease. The cloning and characterization of a novel procoagulant induced by MHV-3 infection of murine macrophages has been reported (6). Fgl2/fibroleukin is an immune coagulant with the ability to directly cleave prothrombin to thrombin (6–10). Initially cloned from CD8+ cytotoxic T cells, Fgl2/fibroleukin protein shares homology of its carboxyl terminus with fibrinogen β and γ chains (11). Fgl2/fibroleukin protein generated in a baculovirus expression system exhibits no measurable prothrombinase activity until reconstituted into negatively charged phospholipid vesicles (e.g., containing phosphatidyl-L-serine) (10). As with factor Xa, catalytic activity is dependent on calcium and is enhanced by factor Va. Site-directed mutagenesis of Ser89 of the murine protein indicated that Fgl2/fibroleukin has the characteristics of a serine protease and that Ser89 was critical for the prothrombinase activity of fgl2. In contrast to factor Xa, the Fgl2/fibroleukin prothrombinase activity is not inhibited by antithrombin III.
The human and murine genes for the Fgl2/fibroleukin prothrombinase have been cloned and characterized and localized to chromosomes 7 and 5, respectively (8, 12). Of note, expression of the Fgl2/fibroleukin prothrombinase mRNA is subject to transcriptional regulation, exhibiting both constitutive and inducible expression. For example, steady-state mRNA expression of Fgl2/fibroleukin prothrombinase is markedly upregulated by IFN-γ (13, 14). In vivo studies indicate robust expression of the Fgl2/fibroleukin prothrombinase in hepatic macrophages and endothelial cells in MHV-3 murine hepatitis models and patients with fulminant hepatic failure (7, 15).
Given that the Fgl2/fibroleukin may be important for both the initiation and localization of fibrin deposition in viral hepatitis, we generated an Fgl2/fibroleukin–deficient mouse. Importantly, we found that fibrin deposition and liver necrosis were markedly reduced and survival was increased in mice infected with the MHV-3 coronavirus. The relevance of these findings to patients with virus-induced liver disease is underscored by the prominent expression of Fgl2/fibroleukin prothrombinase mRNA transcripts and immunoreactive protein, and strong association with fibrin deposition, in liver tissue from patients with marked chronic hepatitis B–induced disease.
All animal experiments in the study were carried out according to the guidelines of the Canadian Council on Animal Care and approved by the University of Toronto and/or University Health Network Committees on Animal Experimentation. Informed consent was obtained from human study participants, and the research protocol was reviewed and approved by the institutional review board of Tonji Hospital, Wuhan, People’s Republic of China.
The targeting construct was derived from a mouse 129Sv/J strain genomic library and transfected into 129Sv/J ES cells by electroporation. Appropriately targeted ES clones were injected into C57Bl/6 blastocysts. Chimeric males were mated with C57Bl/6 females. Mice were interbred from successive generations of Fgl2/fibroleukin+/– founders, and thus littermates represent a mixed 129Sv/J × C57Bl/6 genetic background. Southern blot analysis and multiplex PCR were used to genotype animals (details of probes and oligonucleotides are available from the authors upon request). The 129Sv/J inbred strain and the C57Bl/6 inbred strain are both MHV-3 sensitive (16). To assess the effects of strain background on loss of Fgl2/fibroleukin–/– homozygotes and response to MHV-3 infection, Fgl2/fibroleukin+/– mice were backcrossed with C57Bl/6 inbred mice for ten successive generations. The fidelity of the backcross was assessed by genotyping Fgl2/fibroleukin+/– mice derived from the tenth generation for two informative DNA markers per chromosome (i.e., different alleles in 129Sv/J versus C57Bl/6). Unless stated otherwise, all studies were performed on the mixed 129Sv/J × C57Bl/6 genetic background.
Uteri were removed from euthanized pregnant mice on postcoitum (pc) days 7.5–11.5, were fixed in freshly prepared buffered 4% paraformaldehyde for 18 hours, and then embedded in paraffin. Serial sections were cut and fixed to Aptex-coated slides. Every tenth slide was stained with hematoxylin and eosin. Adjacent sections were stained with polyclonal rabbit anti-fgl2 at 1/10,000 dilution or control rabbit IgG 1.25 μg/ml as described (17), without microwave treatment.
Mice were anesthetized, followed by percutaneous cardiac puncture for blood aspiration. Approximately 500 μl of blood was collected into a Microtainer tube containing EDTA (Becton Dickinson Corp., Franklin Lakes, New Jersey, USA). Hemoglobin level, platelet count, and leukocyte count were performed by the University Health Network Medical Laboratories (Toronto, Ontario, Canada), where the automated equipment was readjusted to standardize for mouse samples. The Hemochron Jr. II Microcoagulation System (International Technidyne Corp., Edison, New Jersey, USA) was used for immediate measurement of prothrombin time and activated partial thromboplastin times. Bleeding times were measured as described (18).
Thioglycollate-elicited macrophages (4 × 106/ml) were exposed in vitro to MHV-3 (MOI 1), 10 μg/ml LPS (Eschericia coli serotype 0111; Sigma-Aldrich, St. Louis, Missouri, USA), or vehicle for 8 hours for procoagulant activity measurements. After three cycles of freezing, thawing, and sonication, extracts were assayed for the capacity to shorten the spontaneous clotting time of normal citrated human plasma in a one-stage clotting assay, as described previously (10). The time for appearance of a fibrin gel was recorded. First-strand cDNA was synthesized using the SuperScript Preamplification protocol (Life Technologies Inc., Rockville, Maryland, USA) followed by RT-PCR amplification using a set of fgl2-specific primers spanning exon 1 and 2 (sense: 5′-TGC TCA AAG AAG TGC GGA CCC T-3′; antisense: 5′-GCC CCA CTG CTT CTC CTT CCT-3′; 430 bp). RT-PCR was also performed in the in vivo setting using tissues harvested from mice injected intraperitoneally with 1,000 PFU of MHV-3. Total cellular RNA was isolated 16 hours after infection, and RT-PCR was performed as described above.
For LPS studies, mice (n = 10 per group, age 3 to 6 months) received LPS (30 mg/kg E. coli serotype O55:B5, intraperitoneally) as well as buprenorphine and saline for analgesia and fluid resuscitation (0.1 mg/kg in 2 ml saline, subcutaneously at t = 0 and 12 hours), respectively. Mice were monitored every 2 hours for 24 hours for morbidity and mortality. Any animals judged to be suffering were euthanized by cervical dislocation. C57Bl/6 and C3H/HeJ strains were used as LPS-sensitive and LPS-hyporesponsive mouse controls, respectively. For MHV-3 studies, mice (n = 10 per group, age 3 to 6 months) were infected via intraperitoneal injection with 1,000 PFU of MHV-3. Multiple independent experiments were performed using different preparations of viral stocks. Following infection, mice were housed in presterilized cages in an isolated environment and given food and water ad libitum. Mortality was scored when animals become moribund. Livers were removed from all euthanized mice and analyzed for viral titers, liver histology, and fibrin deposition. Frozen liver tissue was homogenized and viral titers determined on monolayers of L2 cells in a standard plaque assay (19). For histological examination and quantification of necrosis and fibrin deposition, liver tissue was fixed in 10% buffered formalin for 4 hours followed by routine tissue processing and staining using an automated tissue processor, following which the tissue blocks were embedded in paraffin. Livers were then sectioned 5-μm thick and stained with hematoxylin and eosin and with martius/scarlet/blue. Liver sections were immunostained for fibrin using the Nexes immunostaining method, an automated avidin-biotin method using protease 1 treatment (Ventana Medical Systems, Tuscon, Arizona, USA) in which a purified Ab (a specific biotinylated 1:100 diluted anti-rabbit IgG; Vector Laboratories, Burlingame, California, USA) was used. Sections were scored in a blinded fashion to determine the extent of necrosis and fibrin deposition. The surface area of the liver examined was equal in all instances and corresponded to ten contiguous histological fields at low magnification (×100). Sera from all animals were analyzed quantitatively for alanine aminotransferase (ALT) using a Worthington Statzyme GTP kit (Worthington Biochemical Corp., Lakewood, New Jersey, USA) as described previously (19).
Patients were recruited at Tonji Hospital. Biochemical, histological, and clinical features were used to define patients with chronic viral hepatitis B (marked chronic viral hepatitis B versus minimal chronic viral hepatitis B). Diagnostic criteria and laboratory investigations used standard definitions (20). The evaluation of patients with chronic viral hepatitis B infection included a thorough history and physical examination, with special emphasis on risk factors for coinfection (with hepatitis C, D, or HIV), alcohol use, and family history of viral hepatitis B infection and liver cancer. Percutaneous liver biopsies were obtained for the purposes of guiding treatment decisions (21). Hepatitis B viral markers and serology (hepatitis B surface antigen [HBsAg], hepatitis B e-antigen [HBeAg], anti–hepatitis B viral capsid [anti-HBcAg]) were assessed using ELISA assay kits obtained from Shanghai Shi yue Ke Hua Biological Science Inc. (Shanghai, People’s Republic of China) and/or Abbott Laboratories (Chicago, Illinois, USA) according to the manufacturer’s instructions. Hepatitis B viral DNA loads were assessed by PCR (sense: 5′-TTT GGG GCA TGG ACA TTG AC-3′; antisense: 5′-CCC ACC TTA TGA GTC CAA GG-3′). Twenty-three patients with marked chronic hepatitis B and 13 patients with minimal chronic viral hepatitis B were evaluated. Sections of liver tissue were scored in a blinded fashion as to the histological diagnosis, fibrin deposition, and Fgl2/fibroleukin immunostaining. For fibrin detection, a rabbit–anti-human fibrinogen Ab (DAKO Corp., Carpinteria, California, USA) known to react with fibrinogen and fibrin in human tissues (7) was used. A CD68 Ab (DAKO Corp.) was used to detect macrophages (Kupffer cells). For Fgl2/fibroleukin immunostaining, a polyclonal rabbit Ab was used as described (17). Immunoperoxidase staining (dark brown) used the avidin-biotin complex method. For the in situ hybridization studies, a 169-bp DNA fragment from the carboxyl end of the human Fgl2/fibroleukin coding region was used as a template to synthesize anti-sense digoxigenin-11–UTP-labeled cRNA probes (Hoffman-La Roche AG, Basel, Switzerland) and detected using the alkaline phosphatase method, as described (7).
All data are reported as the mean value plus or minus SEM, with sample sizes stated throughout. Mendelian heritability and survival curves were statistically assessed using the Chi-squared test with a Fisher exact test and Kaplan-Meier survival analysis, respectively (StatView V4.5; Abacus Concepts Inc., San Francisco, California, USA). P values less than 0.05 were considered significant.
To investigate the in vivo role(s) for Fgl2/fibroleukin in the procoagulant response in disease we created and analyzed Fgl2/fibroleukin–deficient mice. A targeting vector for functional fgl2 gene ablation (Figure (Figure1a)1a) was constructed by insertion of a LacZ reporter and PGK-neo gene within the first of two coding exons and mutagenesis of the Fgl2/fibroleukin initiator methionine codon in exon 1. Chimeric mice were generated by injection of targeted ES cell clones (Figure (Figure1b)1b) into C57Bl/6-derived blastocysts by standard approaches. Fgl2/fibroleukin+/– intercrosses produced viable Fgl2/fibroleukin–/– offspring as identified by Southern blot analysis and multiplex PCR (Figure (Figure11c).
Interbreeding of Fgl2/fibroleukin+/– mice produced offspring at ratios that deviated from the expected Mendelian ratios. At weaning, genotyping identified 156, 269, and 86 Fgl2/fibroleukin+/+, Fgl2/fibroleukin+/–, and Fgl2/fibroleukin–/– mice, respectively (observed ratio 1:1.7:0.6 versus expected 1:2:1 ratio; χ2 = 20.6; P < 0.001). Importantly, 40% of Fgl2/fibroleukin–/– homozygotes were lost. At pc day 10.5, genotyping of embryos indicated that an important degree of embryo loss was occurring early in development. To determine when embryo losses occurred, zygotes and uterine tissue were examined by light microscopy and immunohistochemistry using a polyclonal anti-Fgl2 Ab from pc days 7.5–11.5. On pc day 7.5, embryos and uterine decidua appeared normal. Starting at pc day 8.5, many of the Fgl2/fibroleukin–/– embryos showed moderate to severe hemorrhage at implantation sites, with extravasation of maternal erythrocytes between the mural trophectoderm and Reichert’s membrane, especially at the antimesometrial pole (Figure (Figure2).2). Immunohistochemistry revealed that embryos with hemorrhages were Fgl2/fibroleukin deficient in mural trophectoderm. This negative staining contrasted with positive immunostaining in embryos that did not exhibit hemorrhages and the maternal decidua of Fgl2/fibroleukin+/– mothers (Figure (Figure2).2). Embryonic or maternal hemorrhage was otherwise not observed early or late in pregnancy. The loss of Fgl2/fibroleukin–/– homozygotes was not modified significantly on the C57Bl/6 inbred background. When Fgl2/fibroleukin+/– mice were backcrossed with C57Bl/6 inbred mice through ten successive generations and repeated intercrosses of Fgl2/fibroleukin+/–, we again detected loss of Fgl2/fibroleukin–/– homozygotes. At weaning we detected 62 and 14 Fgl2/fibroleukin+/– and Fgl2/fibroleukin–/– mice, respectively (observed ratio 1:0.2 versus expected 1:0.5 ratio; χ2 = 7.6, P < 0.01).
Standard hematological profiles (hemoglobin, white blood cell count, and platelet counts), bleeding times, and prothrombin and partial thromboplastin time estimates in Fgl2/fibroleukin–deficient adult mice were similar to littermate controls (data not shown). Adult Fgl2/fibroleukin–/– mice were unremarkable compared with littermates with respect to gross anatomical examination, bleeding episodes, or longevity (2.5 years observation).
Murine peritoneal macrophages infected in vitro with MHV-3 express a unique cell-surface calcium- and phospholipid-dependent procoagulant with direct prothrombinase activity. Cloning and heterologous expression of the MHV-3–induced procoagulant identified Fgl2/fibroleukin (6, 8, 10). Strain-dependent susceptibility to MHV-3–induced fulminant hepatic failure correlates with the ability of Th1-type lymphocytes to induce expression of Fgl2/fibroleukin (22). Whereas the A/J strain of mice is resistant to fulminant hepatic failure, the C57Bl/6 and CV129 strains are fully susceptible to MHV-3 and die within 4–7 days (23). Importantly, MHV-3 infection failed to induce the Fgl2/fibroleukin mRNA (Figure (Figure1d)1d) or procoagulant activity (Table (Table1)1) in thioglycollate-elicited peritoneal macrophages isolated from Fgl2/fibroleukin–/– mice. LPS is known to induce TF/factor VII–dependent procoagulant activity in peritoneal macrophages. In contrast to the abrogation of MHV-3–induced procoagulant activity, the response to LPS was unaffected in Fgl2/fibroleukin–/– cells (Table (Table11).
Mortality in MHV-3–infected (1,000 PFU) Fgl2/fibroleukin–/– mice was significantly blunted compared with Fgl2/fibroleukin+/+ littermates (Figure (Figure3a),3a), with heterozygotes showing an intermediate phenotype. Infection of A/J and C57Bl/6 mice recapitulated the resistant and susceptible phenotypes reported previously (16). Resistance of Fgl2/fibroleukin–/– mice to MHV-3–induced death was reproducible in multiple independent infections and across different preparations of viral stocks. We assessed the effects of strain background on MHV-3–induced liver necrosis and survival in mice infected with MHV-3. Consistent with findings in the mixed 129Sv/J × C57Bl/6 genetic background, findings indicated that Fgl2/fibroleukin–/– mice on the C57Bl/6 background were also resistant to MHV-3–induced liver necrosis and death (data not shown). The response of Fgl2/fibroleukin–/– mice to systemic inflammation induced by acute exposure to LPS was defined and compared with the LPS-hyporesponsive C3H/HeJ strain. All mouse strains, except for the C3H/HeJ, exhibited signs of illness (mottled fur, inactivity, lethargy). The Fgl2/fibroleukin genotype failed to modify this response. Also, there was no difference in survival between non-C3H/HeJ strains as seen by Kaplan Meier analysis, demonstrating that disruption of the fgl2 gene does not affect systemic LPS responses (Figure (Figure33b).
When we assessed fibrin deposition in the liver and quantified hepatocellular necrosis in the viral hepatitis model (Figure (Figure4),4), we observed effects of MHV-3 infection that were consistent with the phenotypic effect of the Fgl2/fibroleukin genotype on overall mortality, namely markedly decreased fibrin deposition and liver cell necrosis in Fgl2/fibroleukin–/– mice. Marked elevations in serum ALT levels, a biochemical marker of liver cell histopathology (baseline values in normal mice are less than 50 IU/l), were seen 3 days after viral infection in C57Bl/6 and Fgl2/fibroleukin+/+ mice (7,420 IU/l and 6,490 IU/l). This can be contrasted with the trivial injury observed in A/J and Fgl2/fibroleukin–/– mice (54 IU/l and 87 IU/l) or the intermediate response observed in Fgl2/fibroleukin+/– mice (870 IU/l). When assessed at 14 days, modest elevations in ALT levels were evident in surviving Fgl2/fibroleukin–/– mice compared with the resistant A/J strain (625 versus 80 IU/l, P < 0.05). MHV-3 viral loads in the livers of A/J, Fgl2/fibroleukin–/–, Fgl2/fibroleukin+/+, and C57Bl/6 mice 3 days after infection were 8.0, 9.0, 8.2, and 9.0 × 107 PFU/g of tissue, indicating that the Fgl2/fibroleukin genotype did not have a major effect on the production of infectious virus in the liver. Fourteen days after infection, MHV-3 viral loads were significantly higher in surviving Fgl2/fibroleukin–/– mice compared with the resistant A/J strain (6.0 × 109 versus 2.0 × 102 PFU/g liver tissue). This indicates that although Fgl2/fibroleukin–/– mice evidenced an important degree of protection against MHV-3–induced fulminant hepatic failure, in contrast to the resistant A/J strain, they failed to eliminate the virus.
To address the relevance of Fgl2/fibroleukin in human viral hepatitis, we studied patients with chronic hepatitis B. We have reported previously the coexpression of Fgl2/fibroleukin mRNA transcripts and fibrin in the livers of three patients with acute fulminant hepatic failure due to hepatitis B virus, an uncommon but devastating illness (7). In contrast, chronic hepatitis B virus infection is a common disease, with worldwide distribution. This serious clinical problem has protean adverse sequelae, including hepatic cirrhosis and hepatocellular carcinoma. Hepatitis B virus infection is especially endemic in Asia. Twenty-three patients with biochemical, histological, and clinical evidence of marked chronic viral hepatitis B and 13 patients with minimal chronic viral hepatitis B were studied for hepatic Fgl2/fibroleukin expression. Patient characteristics are noted in Table Table2.2. Of note, HBsAg, HBeAg, anti-HBcAg, and hepatitis B viral DNA load did not correlate with expression of Fgl2/fibroleukin or fibrin deposition. Although ALT and total bilirubin levels tended to be higher in patients with marked chronic hepatitis versus minimal chronic hepatitis B, there was considerable overlap in patient values. Twenty-one of 23 patients with marked chronic viral hepatitis B were positive for Fgl2/fibroleukin expression, both of which were confirmed by in situ hybridization and immunohistochemistry. Fgl2/fibroleukin transcripts and immunoreactive protein were seen in macrophages and endothelial cells in areas of hepatic inflammation and necrosis, both in portal areas and in the sinusoids (Figure (Figure5).5). Associated with the Fgl2/fibroleukin expression was fibrin deposition, as shown in Figure Figure5.5. Of the 13 patients with minimal chronic viral hepatitis B (Table (Table2),2), one patient demonstrated Fgl2/fibroleukin and fibrin expression. CD68-positive cells (Kupffer/macrophages) were clearly evident in all patients.
Chronic infection with hepatitis B virus affects an estimated 300 million people on a global basis (24, 25). An estimated 1.25 million people in the United States are chronic carriers, defined as positive for HBsAg for more than 6 months (26). Although most carriers do not develop hepatic complications from chronic hepatitis B, 15–40% will develop serious sequelae during their lifetime, which is why a greater understanding is needed of the pathogenesis of viral-induced hepatocellular injury. We chose to study chronic hepatitis B viral infection in the Asian-Pacific region, where chronic infection is especially prevalent and patients usually acquire the infection at the time of birth or early in childhood. Some of these patients, whose infection originated earlier in life, demonstrate marked chronic hepatitis in the third and fourth decades of life. This disease is characterized by recurrent flares of hepatocellular injury. Minimal chronic viral hepatitis B may reflect either clinical remission of the latter or a more benign disease. Biopsy is necessary to distinguish the two disorders and has a direct influence on therapeutic choices. Flares of marked chronic hepatitis are postulated to reflect T lymphocyte–mediated immune responses to the virus (27). Indeed, T cell–mediated immune responses also play a prominent role in other forms of hepatocellular injury — autoimmune hepatitis, hepatotoxins, and concanavalin A hepatitis (28). It is not clear what explains why patients present with marked chronic hepatitis versus minimal chronic viral hepatitis B or what mediates transition from one form to the other. Intrahepatic production of IFN-γ figures prominently in how viral hepatitis B–specific T cells mediate hepatocellular injury in marked chronic hepatitis (1, 29, 30).
The current study demonstrates that expression of Fgl2/fibroleukin mRNA and protein varies markedly in patients with marked chronic hepatitis B versus those with minimal chronic viral hepatitis B. Expression of Fgl2/fibroleukin is highly correlated with fibrin expression. We have reported previously expression of Fgl2/fibroleukin in three patients with hepatitis B–mediated fulminant hepatic failure, a devastating but rare complication of hepatitis B (7). Taken together with results reported here for marked chronic hepatitis, pharmacologic blockade of Fgl2/fibroleukin may offer an important new treatment approach in hepatitis viral B–induced disease. It is important to stress that these findings identify that an association exists between expression of Fgl2/fibroleukin, a prothrombinase, and the fibrin deposition that attends disease in marked chronic hepatitis B. Whether a cause and effect relationship exists between Fgl2/fibroleukin expression and fibrin deposition requires future studies, such as clinical trials in patients with a specific inhibitor of Fgl2/fibroleukin. Future studies will also need to address how established therapies for hepatitis viral B–induced disease modulate Fgl2/fibroleukin expression, such as the effects of IFN-α.
To begin to define a cause and effect relationship between the Fgl2/fibroleukin prothrombinase and hepatocellular injury in viral hepatitis we developed Fgl2/fibroleukin+/– and Fgl2/fibroleukin–/– mice and examined the effect of Fgl2/fibroleukin genotype on in vitro and in vivo responses to MHV-3. Macrophages from Fgl2/fibroleukin+/+ mice responded to the MHV-3 virus with a robust procoagulant response. In contrast, macrophages from Fgl2/fibroleukin–/– mice generated no increase in procoagulant above control levels. LPS induced a similar procoagulant response in both. LPS is known to induce TF/factor VII–dependent procoagulant activity in peritoneal macrophages. In the presence of calcium, TF/factor VIIa activates the conversion of the zymogen precursor factor X into factor Xa, the classical activator of thrombin generation. Using purified recombinant Fgl2/fibroleukin prothrombinase generated in a baculovirus system and reconstituted into phospholipid-containing vesicles and MHV-3–infected murine peritoneal macrophages, we recently assessed rates of thrombin generation using one-stage clotting assays, 125I-labeled prothrombin cleavage assays, and a chromogenic substrate of thrombin, namely H-D-hexahydrotyrosyl-L-alanyl-L-arginine-p-nitroanalide-diacetate. Like factor Xa, the Fgl2/fibroleukin prothrombinase is dependent on calcium, phospholipids, and factor Va for full activity (10). Fgl2/fibroleukin prothrombinase differs from factor Xa in that activity on cell surfaces of MHV-3–infected peritoneal macrophages is resistant to extensive washing, consistent with the predicted transmembrane structure of the Fgl2/fibroleukin prothrombinase. Activity is not inhibited by antithrombin III and is not dependent on factor VII. The Fgl2/fibroleukin prothrombinase generates a unique thrombin cleavage fragment of approximately 24 kDa (10). Neutralizing Ab’s directed against Fgl2/fibroleukin inhibit MHV-3–induced changes in the one-stage clotting assay (31). Such Ab’s are specific in that they do not react with purified MHV-3– or LPS-induced procoagulants.
Mortality in MHV-3–infected Fgl2/fibroleukin–/– mice was significantly reduced compared with Fgl2/fibroleukin+/+ littermates; therefore, infection of Fgl2/fibroleukin–/– and Fgl2/fibroleukin+/+ mice tended to recapitulate the resistant and susceptible phenotypes reported previously for C57Bl/6 and A/J inbred strains, respectively (16). Also, targeted ablation of the Fgl2/fibroleukin gene and neutralizing Ab’s against the Fgl2/fibroleukin prothrombinase resulted in comparable effects on MHV-3 pathogenesis (23). The response to LPS was not modified by Fgl2/fibroleukin genotype and contrasted with the effect in the LPS-hyporesponsive C3H/HeJ strain. When we assessed fibrin deposition in the liver and quantified hepatocellular necrosis, we observed effects of MHV-3 infection that were consistent with the effect of the Fgl2/fibroleukin genotype on overall mortality, namely, markedly decreased fibrin deposition and hepatocellular injury in Fgl2/fibroleukin–/– mice. Previous studies have suggested the existence of multiple genetic modifiers for the MHV-3–induced fulminant hepatitis phenotype (19), including the CEACAM1 MHV viral receptor glycoprotein (32). MHV-3 viral loads in the livers did not vary with the Fgl2/fibroleukin genotype. This contrasts with the effects of targeted disruption of the CEACAM1 MHV viral receptor, which modifies hepatotrophic host-viral interactions and decreases viral loads in the livers of MHV-3–infected mice (33). We did not detect an important effect of ablating the Fgl2/fibroleukin gene on MHV-3 viral loads in the liver. To the extent that MHV-3 viral hepatitis can be used to model viral hepatitis B in humans, these cumulative findings can be taken to indicate that hepatocellular injury induced by MHV-3 is critically dependent on the Fgl2/fibroleukin prothrombinase.
What are the other biological roles for Fgl2/fibroleukin? When generating the Fgl2/fibroleukin–deficient murine model, we identified loss of Fgl2/fibroleukin–/– mice on both a mixed 129Sv/J × C57Bl/6 genetic background and C57Bl/6 inbred background. Coagulation and procoagulant factor deficiencies are known to result in early or “occult” pregnancy failure due to perturbations at the fetal-maternal interface and can be maternal (34, 35) or fetal in origin (36–39). We have reported previously constitutive Fgl2/fibroleukin prothrombinase mRNA and protein expression on murine trophectoderm (17). Future studies will be necessary to determine whether reconstitution of Fgl2/fibroleukin expression in extraembryonic tissues rescues Fgl2/fibroleukin–/– mice from early lethality or whether loss of Fgl2/fibroleukin–/– mice reflects other important functional contributions of Fgl2/fibroleukin during development. When studying adult Fgl2/fibroleukin–deficient mice, we failed to identify baseline alterations in standard hematological and coagulation profiles or bleeding times. Although adult Fgl2/fibroleukin–/– mice were unremarkable compared with littermates with respect to bleeding episodes or longevity, we anticipate more detailed future analysis of the coagulation cascade.
This Fgl2/fibroleukin prothrombinase bypasses the TF/factor VII extrinsic pathway and directly converts prothrombin to thrombin. Stimuli known to induce expression of the Fgl2/fibroleukin mRNA and protein (e.g, IFN-γ treatment [see ref. 13]), MHV-3 viral infection, xenotransplantation) are distinct from those that elicit TF/factor VII–dependent fibrin generation (e.g., LPS). Future studies will need to define the disease settings in which Fgl2/fibroleukin expression directs local fibrin generation. It is of interest that a coronavirus can induce tissue–specific expression of the Fgl2/fibroleukin prothrombinase. Using a set of parental and recombinant MHV-3 strains, we mapped the viral genetic determinants that induce fulminant hepatitis in susceptible murine strains (40). These studies identified a critical role for the MHV-3 coronavirus nucleocapsid gene product in the transcriptional activation of the gene. Whether coronavirus infection in other species also induces Fgl2/fibroleukin prothrombinase expression remains to be determined. In this respect it will be important to define whether expression of the Fgl2/fibroleukin prothrombinase contributes to pulmonary parenchymal injury in human patients with severe acute respiratory syndrome (SARS), given that coronavirus infection contributes to this newly recognized illness (41–44).
Our results provide compelling evidence for a role of the Fgl2/fibroleukin prothrombinase in viral hepatitis. Collectively, these data argue that the Fgl2/fibroleukin prothrombinase is a logical target for molecular manipulation and offers the hope for the development of new treatment approaches for patients with fulminant and marked chronic viral hepatitis.
This work was supported by operating grants from the Canadian Institutes of Health Research (MOP 37778 to P.A. Marsden; MOP 37777 to G.A. Levy and D.A. Clark). Q. Ning is supported by the Natural Science Foundation of China (NSFC30170846) and is an Outstanding Young Investigator (NSFC30225040). Mouse genotyping was kindly performed by the Mouse Genetic Mapping Facility of the Toronto Centre for Modeling Human Disease. P.A. Marsden is a Heart and Stroke Foundation of Canada Career Investigator.
Philip A. Marsden and Qin Ning contributed equally to this work.
Conflict of interest: The authors have declared that no conflict of interest exists.
Nonstandard abbreviations used: tissue factor (TF); murine hepatitis virus type 3 (MHV-3); postcoitus (pc); alanine aminotransferase (ALT); hepatitis B surface antigen (HBsAg); hepatitis B e-antigen (HBeAg); hepatitis B viral capsid (HBcAg); severe acute respiratory syndrome (SARS).